Suppr超能文献

探索格雷夫斯病超重和肥胖患者治疗后的体重变化:一项回顾性分析

Exploring Post-treatment Weight Changes in Overweight and Obese Patients With Graves' Disease: A Retrospective Analysis.

作者信息

Guia Lopes Maria Leonor, Bello Carlos, Cidade José Pedro, Cunha Clara, Limbert Clotilde, Sequeira Duarte Joao

机构信息

Endocrinology, Centro Hospitalar Lisboa Ocidental - Hospital Egas Moniz, Lisbon, PRT.

Endocrinology, Hospital da Luz Lisboa, Lisbon, PRT.

出版信息

Cureus. 2024 Apr 30;16(4):e59408. doi: 10.7759/cureus.59408. eCollection 2024 Apr.

Abstract

INTRODUCTION

Graves' disease (GD) is associated with primary hyperthyroidism, leading to weight loss before treatment. During the treatment, weight gain is frequently observed, often surpassing the initial weight loss. This study aimed to analyze weight fluctuations in GD patients, focusing on the subset of overweight and obese (OAO) individuals, considering the significant metabolic implications and heightened cardiovascular risk of these weight changes.

METHODS

A retrospective cohort study included 122 GD patients with biochemical primary hyperthyroidism and at least 12 months of clinical follow-up after treatment for analysis. The OAO cohort comprised individuals with a body mass index (BMI) ≥25 kg/m². Data on laboratory, demographic, and weight variables were collected longitudinally.

RESULTS

During the hyperthyroidism state, 34.4% (n=42) of patients presented with weight loss, a phenomenon linked to lower serum thyroid-stimulating hormone levels at diagnosis (p=0.010) and an extended need for anti-thyroid drug treatment (p<0.001). Following treatment, around 60% (n=73) of individuals encountered weight gain, exhibiting a higher prevalence among women (p<0.001) and those undergoing definitive treatment modalities (p=0.024). Notably, 26.2% (n=32) experienced excessive weight gain, which was correlated with higher premorbid BMI and diminished weight loss induced by hyperthyroidism (p<0.001). Within the OAO cohort, 66.7% (n=26) observed an increase in weight post-treatment, and in 28.2% (n=11), excessive weight gain was reported. Weight gain and excessive weight gain were noted in patients with higher initial BMIs.

CONCLUSIONS

This study highlights that post-treatment weight gain is common, emphasizing the need for careful weight management in GD. In OAO GD patients, the association between initial BMI and increased weight underscores potential cardiovascular risks, warranting vigilant monitoring and early intervention.

摘要

引言

格雷夫斯病(GD)与原发性甲状腺功能亢进有关,导致治疗前体重减轻。在治疗期间,经常观察到体重增加,且往往超过最初的体重减轻幅度。本研究旨在分析GD患者的体重波动情况,重点关注超重和肥胖(OAO)个体子集,考虑到这些体重变化具有重大的代谢影响和更高的心血管风险。

方法

一项回顾性队列研究纳入了122例患有生化原发性甲状腺功能亢进且治疗后至少有12个月临床随访的GD患者进行分析。OAO队列包括体重指数(BMI)≥25 kg/m²的个体。纵向收集实验室、人口统计学和体重变量的数据。

结果

在甲状腺功能亢进状态下,34.4%(n = 42)的患者出现体重减轻,这一现象与诊断时较低的血清促甲状腺激素水平(p = 0.010)以及更长时间的抗甲状腺药物治疗需求(p < 0.001)有关。治疗后,约60%(n = 73)的个体出现体重增加,在女性(p < 0.001)和接受确定性治疗方式的患者中患病率更高(p = 0.024)。值得注意的是

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b741/11139545/db2f89424927/cureus-0016-00000059408-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验